Publication | Closed Access

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

UrologyGetug 12Genitourinary CancerMedicineAndrogen Deprivation TherapyPharmacotherapyProstatic DiseaseOncologyRadiation OncologyEndocrine-related CancerPhase 3